NO3049208T3 - - Google Patents

Info

Publication number
NO3049208T3
NO3049208T3 NO14741534A NO14741534A NO3049208T3 NO 3049208 T3 NO3049208 T3 NO 3049208T3 NO 14741534 A NO14741534 A NO 14741534A NO 14741534 A NO14741534 A NO 14741534A NO 3049208 T3 NO3049208 T3 NO 3049208T3
Authority
NO
Norway
Application number
NO14741534A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3049208(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3049208T3 publication Critical patent/NO3049208T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO14741534A 2012-12-14 2014-06-30 NO3049208T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
NO3049208T3 true NO3049208T3 (fr) 2018-04-14

Family

ID=50934967

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14741534A NO3049208T3 (fr) 2012-12-14 2014-06-30

Country Status (12)

Country Link
US (3) US9822347B2 (fr)
EP (2) EP3326622B1 (fr)
JP (2) JP6345690B2 (fr)
AU (3) AU2013359179B2 (fr)
CA (1) CA2894539C (fr)
DK (2) DK2931265T6 (fr)
ES (2) ES2862335T3 (fr)
FI (1) FI2931265T6 (fr)
HK (1) HK1256071A1 (fr)
NO (1) NO3049208T3 (fr)
PT (2) PT3326622T (fr)
WO (1) WO2014093690A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091305A2 (fr) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la signalisation axl dans une thérapie antimétastasique
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
WO2013090776A1 (fr) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la signalisation axl/gas6 dans le traitement d'une maladie
DK2931265T6 (da) 2012-12-14 2023-05-01 Univ Leland Stanford Junior Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi
CA2909669C (fr) 2014-10-20 2023-12-12 Ruga Corporation Activite antivirale de l'inhibiteur gas6
CA2971406A1 (fr) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Activite antifibrotique d'inhibiteur de gas6
AU2018359863A1 (en) * 2017-11-04 2020-07-02 Aravive Biologics, Inc Methods of treating metastatic cancers using axl decoy receptors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (fr) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030032102A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (fr) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnostic et traitement de l'invasion des cellules cancéreuses
WO2004108748A2 (fr) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Peptides du gene 6 specifique de l'arret de croissance, anticorps, compositions, procedes et utilisations associes
AU2004231036A1 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
EP1825005B1 (fr) 2004-11-24 2015-07-15 The Regents of the University of Colorado, a body corporate Agents diagnostiques et therapeutiques a base de mer
EP1897940A4 (fr) 2005-05-02 2009-04-15 Toray Industries Composition et procédé permettant de diagnostiquer un cancer oesophagien et une métastase d'un cancer oesophagien
US8168415B2 (en) * 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
JP2010523712A (ja) 2007-04-13 2010-07-15 スーパージェン， インコーポレイテッド 癌または過剰増殖の治療に有用なａｘｌキナーゼ阻害剤
EP2170395A1 (fr) 2007-07-02 2010-04-07 Wyeth LLC Modulateurs de axl pour le traitement de troubles osseux
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
MX2011006621A (es) * 2008-12-19 2011-07-12 Novartis Ag Polipeptidos solubles para uso en el tratamiento de trastornos autoinmunes e inflamatorios.
CN102421802B (zh) * 2009-05-11 2014-08-20 U3制药有限公司 人源化的axl抗体
WO2011091305A2 (fr) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la signalisation axl dans une thérapie antimétastasique
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
DK2638173T3 (da) 2010-11-08 2019-09-30 Univ Leland Stanford Junior Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
WO2013090776A1 (fr) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la signalisation axl/gas6 dans le traitement d'une maladie
DK2931265T6 (da) 2012-12-14 2023-05-01 Univ Leland Stanford Junior Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
WO2015030849A1 (fr) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University Liaison à haute affinité à gas6
CA2971406A1 (fr) * 2014-12-18 2016-06-23 Aravive Biologics, Inc. Activite antifibrotique d'inhibiteur de gas6

Also Published As

Publication number Publication date
JP2016510309A (ja) 2016-04-07
WO2014093690A1 (fr) 2014-06-19
EP2931265A4 (fr) 2016-08-31
EP3326622A1 (fr) 2018-05-30
AU2017272193A1 (en) 2017-12-21
PT3326622T (pt) 2021-04-07
HK1256071A1 (zh) 2019-09-13
EP3326622B1 (fr) 2021-01-20
DK2931265T3 (en) 2018-04-16
US20220220458A1 (en) 2022-07-14
EP2931265A1 (fr) 2015-10-21
US20150315553A1 (en) 2015-11-05
AU2019210662A1 (en) 2019-08-22
EP2931265B1 (fr) 2018-01-31
AU2013359179A1 (en) 2015-07-02
AU2013359179B2 (en) 2017-10-05
FI2931265T6 (fi) 2023-05-23
DK3326622T3 (da) 2021-04-06
PT2931265T (pt) 2018-04-16
US20180030422A1 (en) 2018-02-01
ES2862335T3 (es) 2021-10-07
JP6832887B2 (ja) 2021-02-24
ES2665323T7 (es) 2023-06-15
JP2018154641A (ja) 2018-10-04
US11136563B2 (en) 2021-10-05
CA2894539A1 (fr) 2014-06-19
JP6345690B2 (ja) 2018-06-20
AU2019210662B2 (en) 2021-07-01
CA2894539C (fr) 2021-09-28
DK2931265T6 (da) 2023-05-01
ES2665323T3 (es) 2018-04-25
US9822347B2 (en) 2017-11-21
EP2931265B3 (fr) 2023-04-05

Similar Documents

Publication Publication Date Title
BR112014017635A2 (fr)
BR112014017614A2 (fr)
BR112014017592A2 (fr)
BR112014017659A2 (fr)
BR112014017646A2 (fr)
BR112014017638A2 (fr)
BR112014018648A2 (fr)
AR092201A1 (fr)
BR112014017607A2 (fr)
BR112013027865A2 (fr)
BR112014017634A2 (fr)
BR112014017609A2 (fr)
BR112014017644A2 (fr)
BR112014017647A2 (fr)
BR112014017588A2 (fr)
BR112014017618A2 (fr)
BR112014013184A8 (fr)
BR112014017630A2 (fr)
BR112014017652A2 (fr)
BR112014017621A2 (fr)
BR112014017627A2 (fr)
BR112014017641A2 (fr)
BR112014017631A2 (fr)
BR112014017636A2 (fr)
NO3049208T3 (fr)